← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

111, Inc. (YI) 10-Year Financial Performance & Capital Metrics

YI • • Industrial / General
HealthcarePharmaceuticalsSpecialty Pharmaceuticals & DistributionIntegrated Healthcare Distribution
About111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services that include online consultation services and electronic prescription services to consumers. It offers prescription and over-the counter drugs, including western and traditional Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices comprising bandages and thermometers; and personal care products consisting of skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Pharmacy, which include pharmacies and wholesalers; and data and supply chain integration services. As of December 31, 2021, it operated 14 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Tianjin, Kunshan, Chongqing, and Wuhan provinces. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.Show more
  • Revenue $14.4B -3.7%
  • EBITDA $19M +105.8%
  • Net Income -$65M +83.5%
  • EPS (Diluted) -7.52 +83.9%
  • Gross Margin 5.76% +91.9%
  • EBITDA Margin 0.13% +106.0%
  • Operating Margin 0.01% +100.6%
  • Net Margin -0.45% +82.9%
  • ROE -19.71% +76.8%
  • ROIC 1.09% +100.9%
  • Debt/Equity 0.67 -58.0%
  • Interest Coverage 0.07 +100.4%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong Piotroski F-Score: 7/9
  • ✓Strong 5Y sales CAGR of 29.5%
  • ✓Trading at only 0.1x book value
  • ✓Efficient asset utilization: 5.2x turnover

✗Weaknesses

  • ✗Weak momentum: RS Rating 9 (bottom 9%)
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y29.51%
3Y5.04%
TTM-3.69%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM77.63%

EPS CAGR

10Y-
5Y-
3Y-
TTM78.07%

ROCE

10Y Avg-41.99%
5Y Avg-40.14%
3Y Avg-35.2%
Latest0.54%

Peer Comparison

Integrated Healthcare Distribution
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
YI111, Inc.28.99M5.72-0.76-3.66%-0.52%-22.96%100%0.67
HITIHigh Tide Inc.218.65M2.51-46.067.1%-1.76%-6.82%11.8%0.51

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+873.84M959.49M1.79B3.95B8.2B12.43B13.52B14.95B14.4B
Revenue Growth %-0.1%0.86%1.21%1.08%0.51%0.09%0.11%-0.04%
Cost of Goods Sold+796.23M868.72M1.68B3.79B7.84B11.8B12.68B14.5B13.57B
COGS % of Revenue0.91%0.91%0.94%0.96%0.96%0.95%0.94%0.97%0.94%
Gross Profit+77.61M90.77M104.27M165.18M365.83M621.1M839.98M448.44M829.23M
Gross Margin %0.09%0.09%0.06%0.04%0.04%0.05%0.06%0.03%0.06%
Gross Profit Growth %-0.17%0.15%0.58%1.21%0.7%0.35%-0.47%0.85%
Operating Expenses+441.89M344.79M504.64M658.7M839.14M1.26B1.21B798.54M827.12M
OpEx % of Revenue0.51%0.36%0.28%0.17%0.1%0.1%0.09%0.05%0.06%
Selling, General & Admin443.88M347.52M503.98M654.96M527.84M720.13M663.5M672.59M384.8M
SG&A % of Revenue0.51%0.36%0.28%0.17%0.06%0.06%0.05%0.04%0.03%
Research & Development61.77M48.13M71.25M61.9M92.08M189.28M139.5M00
R&D % of Revenue0.07%0.05%0.04%0.02%0.01%0.02%0.01%--
Other Operating Expenses-3.35M4.23M11.53M-58.17M219.23M353.82M407.97M125.95M442.31M
Operating Income+-364.28M-254.02M-400.38M-493.51M-473.31M-642.14M-371M-350.1M2.11M
Operating Margin %-0.42%-0.26%-0.22%-0.12%-0.06%-0.05%-0.03%-0.02%0%
Operating Income Growth %-0.3%-0.58%-0.23%0.04%-0.36%0.42%0.06%1.01%
EBITDA+-352.22M-239.2M-389.11M-481.85M-459.29M-614.92M-330.18M-328.32M19.08M
EBITDA Margin %-0.4%-0.25%-0.22%-0.12%-0.06%-0.05%-0.02%-0.02%0%
EBITDA Growth %-0.32%-0.63%-0.24%0.05%-0.34%0.46%0.01%1.06%
D&A (Non-Cash Add-back)12.06M14.82M11.27M11.67M14.02M27.22M40.82M21.78M16.97M
EBIT-362.69M-249.27M-400.38M-498.2M-473.31M-615.54M-362.63M-333.04M7.65M
Net Interest Income+1.56M3.96M4.35M1.18M-2.5M4.29M-5.33M-11.31M-21.29M
Interest Income2.31M4.01M4.35M4.8M6.31M9.78M8.12M8.83M7.04M
Interest Expense751K55K03.62M8.82M5.49M13.44M20.14M28.33M
Other Income/Expense834K4.7M18.34M-8.31M6.2M21.11M-5.07M-3.08M-22.79M
Pretax Income+-363.45M-249.33M-382.03M-501.83M-467.11M-621.02M-376.07M-353.18M-20.68M
Pretax Margin %-0.42%-0.26%-0.21%-0.13%-0.06%-0.05%-0.03%-0.02%-0%
Income Tax+-3.37M08K0000251K96K
Effective Tax Rate %1%1%0.99%1%0.98%1.08%1.11%1.11%3.13%
Net Income+-362.68M-248.58M-380.09M-501.83M-456.53M-669.81M-416.88M-392.69M-64.74M
Net Margin %-0.42%-0.26%-0.21%-0.13%-0.06%-0.05%-0.03%-0.03%-0%
Net Income Growth %-0.31%-0.53%-0.32%0.09%-0.47%0.38%0.06%0.84%
Net Income (Continuing)-363.45M-249.33M-382.04M-501.83M-467.11M-621.02M-376.07M-353.43M-20.78M
Discontinued Operations000000000
Minority Interest2.19M1.44M-512K-2.73M973.24M1.02B1.06B859.55M1.02B
EPS (Diluted)+-100.74-69.04-76.44-60.16-55.40-80.76-50.04-46.58-7.52
EPS Growth %-0.31%-0.11%0.21%0.08%-0.46%0.38%0.07%0.84%
EPS (Basic)-116.10-69.04-76.44-60.16-55.40-80.76-50.04-46.58-7.52
Diluted Shares Outstanding3.6M3.6M4.97M8.18M8.24M8.29M8.33M8.43M8.62M
Basic Shares Outstanding3.12M3.6M4.97M8.18M8.24M8.29M8.33M8.43M8.62M
Dividend Payout Ratio---------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+900.81M730.47M1.51B1.48B2.87B2.8B3.24B2.93B2.65B
Cash & Short-Term Investments640.33M461.19M1.11B613.75M1.49B843.95M879.53M653.67M462.29M
Cash Only373.5M167.66M853.74M613.75M1.19B661.39M673.67M603.52M462.29M
Short-Term Investments266.82M293.53M252.81M0300.17M182.56M205.86M50.14M0
Accounts Receivable28.39M20.4M87.4M88.83M175.68M495.2M600.49M647.48M630.72M
Days Sales Outstanding11.867.7617.868.27.8214.5516.2215.8115.99
Inventory134.73M144.06M210.84M486.27M766.53M1.12B1.5B1.42B1.39B
Days Inventory Outstanding61.7660.5345.7646.8735.734.6643.1635.7337.31
Other Current Assets97.36M102.93M156.11M285.33M432.59M332M250.25M206.88M62.82M
Total Non-Current Assets+40.8M32.92M39.32M128.86M153.78M344.1M237.99M155.71M138.09M
Property, Plant & Equipment24.49M17.03M20.3M117.69M142.07M314.1M212.37M138.14M121.97M
Fixed Asset Turnover35.68x56.35x87.97x33.58x57.74x39.56x63.65x108.21x118.07x
Goodwill00005.6M0000
Intangible Assets5.31M4.75M4.5M8.02M920K4.91M3.27M2.26M1.44M
Long-Term Investments11M11.14M11.14M140K140K3M2M2M0
Other Non-Current Assets003.38M3.01M5.06M22.09M20.35M13.31M14.68M
Total Assets+941.61M763.38M1.55B1.61B3.03B3.15B3.47B3.09B2.79B
Asset Turnover0.93x1.26x1.15x2.45x2.71x3.95x3.89x4.84x5.17x
Asset Growth %--0.19%1.03%0.04%0.88%0.04%0.1%-0.11%-0.1%
Total Current Liabilities+172.15M201.16M314.52M745.63M1.63B2.13B2.73B2.75B2.34B
Accounts Payable97.98M128.14M212.26M444.33M1.07B1.35B1.76B1.59B1.72B
Days Payables Outstanding44.9253.8446.0742.8349.9941.6650.8239.9946.3
Short-Term Debt00095.08M229.25M259.66M178.99M338.07M160.98M
Deferred Revenue (Current)1000K1000K1000K1000K1000K1000K1000K1000K1000K
Other Current Liabilities32.32M37.66M50.68M-7.12M67.03M69.29M190.54M504.16M90.5M
Current Ratio5.23x3.63x4.79x1.99x1.76x1.32x1.19x1.07x1.13x
Quick Ratio4.45x2.92x4.12x1.33x1.29x0.79x0.64x0.55x0.54x
Cash Conversion Cycle28.714.4517.5512.25-6.477.558.5611.557
Total Non-Current Liabilities+193.93M243.41M8.13M90.74M66.12M167.15M100.47M67.87M64.41M
Long-Term Debt000000000
Capital Lease Obligations00057.01M62.39M165.61M100.47M62.62M55.45M
Deferred Tax Liabilities000000000
Other Non-Current Liabilities193.93M243.41M8.13M5.94M3.74M1.54M05.25M8.96M
Total Liabilities366.08M444.56M322.65M836.37M1.7B2.3B2.83B2.81B2.41B
Total Debt+000208.76M329.35M491.01M344.19M443.23M256.77M
Net Debt-373.5M-167.66M-853.74M-461.65M-860.27M-170.38M-329.48M-160.29M-205.52M
Debt / Equity---0.27x0.25x0.58x0.53x1.61x0.67x
Debt / EBITDA--------13.46x
Net Debt / EBITDA---------10.77x
Interest Coverage-485.06x-4618.58x--136.25x-53.68x-117.01x-27.60x-17.38x0.07x
Total Equity+575.52M318.82M1.22B773.92M1.33B848.71M648.24M276.1M380.76M
Equity Growth %--0.45%2.84%-0.37%0.72%-0.36%-0.24%-0.57%0.38%
Book Value per Share159.8788.56246.1094.57161.50102.3477.8032.7544.19
Total Shareholders' Equity573.34M317.38M1.22B776.66M357.4M-173.32M-414.6M-583.45M-642.64M
Common Stock25K25K54K55K55K56K56K57K58K
Retained Earnings-755.06M-1B-1.38B-1.88B-2.34B-3.01B-3.43B-3.82B-3.88B
Treasury Stock000-22.99M-34.97M-40.86M-40.86M-5.89M-5.89M
Accumulated OCI64.87M47.55M67.07M76.44M62.91M59.37M75.59M72.51M74.36M
Minority Interest2.19M1.44M-512K-2.73M973.24M1.02B1.06B859.55M1.02B

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-388.65M-204.37M-343.02M-510.19M-116.78M-688.84M-23.15M-447.24M263.02M
Operating CF Margin %-0.44%-0.21%-0.19%-0.13%-0.01%-0.06%-0%-0.03%0.02%
Operating CF Growth %-0.47%-0.68%-0.49%0.77%-4.9%0.97%-18.32%1.59%
Net Income-363.45M-249.33M-382.04M-501.83M-456.53M-621.02M-376.07M-353.43M-20.78M
Depreciation & Amortization12.06M14.82M11.27M11.67M14.02M27.22M40.82M21.78M16.97M
Stock-Based Compensation3.44M9.92M51.36M54.28M75.69M145.59M162.07M226.69M20.15M
Deferred Taxes001.95M3.55M-89.71M86.36M000
Other Non-Cash Items22K-10K-11.71M25.39M334.79M42.88M105.56M82.05M54.01M
Working Capital Changes-40.72M20.22M-13.84M-103.26M4.97M-369.87M44.46M-424.33M192.66M
Change in Receivables1.98M7.99M-8.17M-36.68M-98.28M-242.4M-86.98M-49.9M121.97M
Change in Inventory-22.03M-9.32M-66.78M-276.23M24.22M-400.55M-406.29M59.59M28.11M
Change in Payables8.94M30.16M84.12M232.08M629.02M274M417.5M-176.74M132.73M
Cash from Investing+-267.55M-36.13M44.45M237.53M-324.67M60.14M-47.17M151.74M37.38M
Capital Expenditures-6.92M-6.86M-14.82M-24.61M-25.5M-62.69M-31.57M-9.82M-15.2M
CapEx % of Revenue0.01%0.01%0.01%0.01%0%0.01%0%0%0%
Acquisitions---------
Investments---------
Other Investing-1.3M-5K-275K-4.55M-324.67M216K-2.99M1.65M458K
Cash from Financing+148.42M49.5M972.7M106.95M1.07B74.34M22.73M205.98M-406.24M
Debt Issued (Net)---------
Equity Issued (Net)---------
Dividends Paid000000000
Share Repurchases---------
Other Financing195.92M49.5M034.86M941.89M49.82M103.13M36.25M-229.16M
Net Change in Cash---------
Free Cash Flow+-395.57M-211.23M-357.84M-534.8M-142.28M-751.53M-54.73M-457.07M247.82M
FCF Margin %-0.45%-0.22%-0.2%-0.14%-0.02%-0.06%-0%-0.03%0.02%
FCF Growth %-0.47%-0.69%-0.49%0.73%-4.28%0.93%-7.35%1.54%
FCF per Share-109.88-58.68-71.96-65.35-17.27-90.62-6.57-54.2228.76
FCF Conversion (FCF/Net Income)1.07x0.82x0.90x1.02x0.26x1.03x0.06x1.14x-4.06x
Interest Paid000000010.42M6.16M
Taxes Paid008K0000251K96K

Key Ratios

Metric201620172018201920202021202220232024
Return on Equity (ROE)-63.02%-55.59%-49.28%-50.24%-43.38%-61.47%-55.7%-84.97%-19.71%
Return on Invested Capital (ROIC)-135.24%-107.89%-115.23%-100.18%-84.59%-83.85%-55.81%-120.84%1.09%
Gross Margin8.88%9.46%5.84%4.18%4.46%5%6.21%3%5.76%
Net Margin-41.5%-25.91%-21.28%-12.7%-5.57%-5.39%-3.08%-2.63%-0.45%
Debt / Equity---0.27x0.25x0.58x0.53x1.61x0.67x
Interest Coverage-485.06x-4618.58x--136.25x-53.68x-117.01x-27.60x-17.38x0.07x
FCF Conversion1.07x0.82x0.90x1.02x0.26x1.03x0.06x1.14x-4.06x
Revenue Growth-9.8%86.14%121.28%107.57%51.48%8.78%10.59%-3.66%

Revenue by Segment

2018201920202021202220232024
Product1.77B3.93B8.16B12.33B13.4B14.84B14.29B
Product Growth-121.99%107.56%51.19%8.69%10.73%-3.69%
Drugs1.49B3.6B7.4B11.68B12.57B13.88B13.4B
Drugs Growth-141.32%105.77%57.89%7.63%10.42%-3.49%
Nutritional Supplements190.43M245.64M559.24M-554.79M631.12M550.46M
Nutritional Supplements Growth-29.00%127.66%--13.76%-12.78%
Other Products16.03M20.35M46.53M-111.1M170.23M201.83M
Other Products Growth-26.95%128.68%--53.23%18.56%
Medical Supplies And Devices26.56M50.18M149.05M-164.92M157.5M144.28M
Medical Supplies And Devices Growth-88.90%197.04%---4.49%-8.39%
Service15.74M22.36M46.48M94.2M113.26M106.22M106.51M
Service Growth-42.00%107.94%102.64%20.24%-6.22%0.27%
MP Service---52.31M68.48M70.27M65.54M
MP Service Growth----30.91%2.62%-6.74%
Service, Other----44.78M35.95M40.97M
Service, Other Growth------19.73%13.98%
Nutritional supplements---442.5M---
Nutritional supplements Growth-------
Medical supplies and devices---124.92M---
Medical supplies and devices Growth-------
Other products.---83.14M---
Other products. Growth-------
Other Services---41.89M---
Other Services Growth-------
Contact lenses.---38K---
Contact lenses. Growth-------
Mp Service12.38M17.24M30.53M----
Mp Service Growth-39.31%77.12%----
Service Other3.37M5.12M15.95M----
Service Other Growth-51.90%211.81%----
Contact Lenses47.3M18.11M3.42M----
Contact Lenses Growth--61.71%-81.12%----

Frequently Asked Questions

Growth & Financials

111, Inc. (YI) reported $14.18B in revenue for fiscal year 2024. This represents a 1523% increase from $873.8M in 2016.

111, Inc. (YI) saw revenue decline by 3.7% over the past year.

111, Inc. (YI) reported a net loss of $74.1M for fiscal year 2024.

Dividend & Returns

111, Inc. (YI) has a return on equity (ROE) of -19.7%. Negative ROE indicates the company is unprofitable.

111, Inc. (YI) generated $97.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.